Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beyond AirXAIR -2.33%23 Debt-to-Equity is 11.82 as of Jun. 2026, which is 7288% above its 10-year median of 0.16. GuruFocus rates XAIR with a GF Score™ of 23/100 and a GF Value™ of $401.70 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 700 Medical Devices & Instruments companies, Beyond Air ranks worse than 99.29% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Beyond Air's Debt-to-Equity or its related term are showing as below:
XAIR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.88 Med: 0.16 Max: 11.82
Current: 11.82
During the past 12 years, the highest Debt-to-Equity Ratio of Beyond Air was 11.82. The lowest was -0.88. And the median was 0.16.
XAIR's Debt-to-Equity is ranked worse than 99.29% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs XAIR: 11.82
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Beyond Air Debt-to-Equity Related Terms
Beyond Air Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Beyond Air's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XAIR vs POAS, RMSL, LUDG: Debt-to-Equity Comparison
For the Medical Devices subindustry, Beyond Air's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Beyond Air's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (XAIR) has a Debt-to-Equity of 11.82 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Beyond Air and its competitors. This is 7288% above median its historical median of 0.16. According to the industry distribution chart, Beyond Air ranks #695 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 99.3%.
Is Beyond Air's Debt-to-Equity too high?
Beyond Air's current Debt-to-Equity of 11.82 is 7288% above median its 10-year median of 0.16. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Beyond Air's value of 11.82 is 5039.1% above this industry median. Based on the distribution chart, Beyond Air ranks #695 out of 700 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beyond Air has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's Debt-to-Equity compare to POAS and RMSL?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #695 out of 700 companies for Debt-to-Equity. This places Beyond Air in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Beyond Air's value of 11.82 is 5039.1% above this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 0.23, Beyond Air has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beyond Air's current Debt-to-Equity of 11.82 is 5039.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Beyond Air and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current Debt-to-Equity is 11.82, which is 7288% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Based on GuruFocus' analysis, Beyond Air (XAIR) is currently considered Possible Value Trap. The stock's GF Value™ is $401.70, compared to a current price of $5.04 — trading 98.7% below its estimated fair value. The current Debt-to-Equity is 11.82, which is 7288% above median its 10-year median of 0.16 and 5039.1% above the Medical Devices & Instruments industry median of 0.23. Beyond Air's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Beyond Air (XAIR), the current Debt-to-Equity is 11.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (XAIR) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of $5.04 is trading 98.7% below its estimated GF Value™ of $401.70.
GuruFocus considers Beyond Air to be Possible Value Trap.
Key valuation signals for XAIR:
Debt-to-Equity: 11.82 (7288% above median its 10-year median of 0.16)
GF Value™: $401.70 vs. price of $5.04 (98.7% below fair value)
Industry Position: 5039.1% above the Medical Devices & Instruments median (#695 of 700)
No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
23GF Score
Get the complete analysis for XAIR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAIR has been successfully added to your 
